Can-Fite BioPharma CEO to Present at NobleCon21 Emerging Growth Equity Conference
ByAinvest
Wednesday, Nov 26, 2025 7:08 am ET1min read
CANF--
Can-Fite BioPharma's CEO, Motti Farbstein, will present at NobleCon21 on December 3rd, 2025, discussing the company's advanced stage drug development pipeline, including Phase III liver cancer, Phase IIa pancreatic cancer, and Phase III psoriasis trials. Additionally, Can-Fite has out-licensing agreements worth up to $130 million for pharma indications and an additional up to $32 million.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet